She had won cancer once already!
A 52-year-old woman with ovarian cancer, on olaparib for maintenance therapy.
For five months, this targeted PARP inhibitor drug had kept her cancer stable, giving her precious time with her family.
But now, two weeks into a low-grade fever and chest tightness, she was fighting a different battle.
One with an evasive enemy.
One her doctors couldn't find.
One that every test said wasn't there.
Her chest CT showed something terrifying: diffuse ground-glass opacities spreading across both lungs like a storm. (AKA a very vicious pneumonia 🌸)
Sometimes, the treatment that saves from cancer leaves one defenseless against something else entirely.
The local hospital had tried everything.
Levofloxacin for typical bacteria.
Meropenem for resistant organisms.
Fluconazole for possible fungal infection.
A week of broad-spectrum antibiotics (aka the kitchen sink) that should have covered nearly every common pathogen.
Nothing was working.
Her fever persisted, hovering around 38°C. The chest tightness was not going away.
And those ground-glass opacities on her chest CT? They just sat there, diffuse and ominous, not responding to treatment.
By the time she arrived at the tertiary hospital, the medical team assessed the situation
Fever of unknown origin (aka FUO 🌸)
Bilateral ground-glass opacities throughout both lungs (aka Bad Pneumonia 🌸)
Failed empirical antibiotic coverage (aka Antibiotics useless 🌸)
And profoundly suppressed immune system (aka Body's defense toast 🌸)
The cancer drug had done its job against her cancer, but did it also strip away the immune defenses that protect against infections?
The medical team aka Infectious Disease detectives 🕵🏼♂️ launched an exhaustive search .
They tested for everything 🙌🏾:
respiratory syncytial virus, adenovirus, influenza A and B, parainfluenza, Coxiella burnetii, Chlamydia pneumoniae, Mycoplasma pneumoniae, Legionella pneumophila.
Blood cultures.
Sputum cultures.
Auto-immune disease panel.
Every single test came back negative 😳.
In an immunocompromised cancer patient, this CT imaging (PNEUMONIA) pattern could mean almost anything:
Fungal infection (Aspergillosis? Pneumocystis?)
Tuberculosis spreading through the lungs
Opportunistic bacterial infection
Drug-induced lung toxicity
Even cancer progression
But without identifying the culprit, your guess is as good as mine😅
The patient declined a lung biopsy - which means cutting into the lung tissue to check for what's actually causing the inflammation.
Too invasive. Too risky. I can't blame her ❤️🩹
When Traditional Medicine Hits the Wall
Let us think 🧐 about the impossible situation this medical team faced.
An immunocompromised cancer patient with obvious pulmonary infection. Bilateral lung involvement. Failed antibiotic therapy.
And every traditional diagnostic test coming back empty.
How do you treat an infection you can't identify?
This is a nightmare scenario that keeps us, Infectious Disease doctors, awake at night
especially in cancer patients where the antibiotic choice could make the difference between the patient staying alive or dying.
Do you give more broad-spectrum antibiotics and hope something works?
Do you start anti-fungals blindly?
What about anti-tuberculosis therapy just in case?
Every day without the right treatment is another day for the infection to spread.
Traditional diagnostics had completely failed 🫣.
But thankfully, the team made a vital decision that would save her life:
🎉 Within 48 hours, the answer emerged from millions of DNA fragments:
Actinomyces odontolyticus — 1,152 unique sequence reads mapping to this organism's genome. Relative abundance of 15.48%. Coverage of 4.05%.
Not a maybe. Not a possible contaminant.
A rare, fastidious bacterium that traditional cultures had completely missed.
Actinomyces odontolyticus is one of medicine's great mimics.
This slow-growing anaerobic bacterium lives peacefully in everyone's mouth🤑as part of normal oral flora.
But, In immunocompromised patients — like this patient— it can invade the lungs and cause devastating infection.
It almost never grows in standard bacterial cultures and without treatment, mortality can reach 28%.
And here's the tragic irony: actinomycosis is completely curable with the right antibiotic. But you have to know what you're treating.
she was started on a simple regimen of high-dose penicillin G every 8 hours
The response was dramatic 🥁.
Her fever stopped.
Her labs improved to normal.
Her Chest CT improved to normal.
The Metagenomics (mNGS) Difference
Here's what makes metagenomic next-generation sequencing transformative in cases like this:
🌸 It's hypothesis-free. You don't need to guess what organism you're looking for. It sequences everything and tells you what's there.
🌸 It works on multiple sample types. Blood, bronchoalveolar lavage fluid, tissue, cerebrospinal fluid, pleural fluid, any sample with microbial DNA.
🌸 It detects rare pathogens. Organisms so unusual that most clinicians have never seen them. Pathogens that PCR tests don't look for because they're too uncommon.
🌸 It provides results in 24-48 hours. Not the days to weeks required for cultures.
🌸 It can identify multiple organisms simultaneously. Perfect for polymicrobial or mixed infections.
In this case, mNGS found Actinomyces odontolyticus — representing 5.6% of actinomycosis cases, in a patient whose cultures were all negative, without requiring invasive lung biopsy.
The Broader Implications
This case is more than just about one cancer patient who survived a rare infection.
It is about the changing landscape of infectious disease risk in modern medicine.
As we develop more effective cancer therapies — PARP inhibitors, checkpoint inhibitors, CAR-T cells, targeted agents — we're creating populations of patients who are living longer but are also immunosuppressed.
According to published research, the incidence of opportunistic infections in cancer patients is rising:
21% bacterial pneumonia rate after chemotherapy in acute leukemia
5% pneumonia incidence in lung cancer patients on therapy
10% in head and neck cancer patients
Organisms from patients' own microbiomes becoming invasive pathogens.
Traditional diagnostics are not equipped for this new reality.
We need tools that can identify rare, fastidious, culture-negative organisms rapidly enough to start targeted therapy before patients deteriorate.
The details of this case have been shared to educate healthcare professionals about the emerging infectious disease risks in cancer patients on targeted therapies and the critical role of metagenomic sequencing in identifying culture-negative opportunistic infection